Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Is scheduled to undergo a unilateral open inguinal herniorrhaphy with mesh under general anesthesia.~* Has an American Society of Anesthesiologists Physical Status of I, II, or III.~* Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable contraceptives.~Exclusion Criteria:~* Had any prior inguinal hernia repair.~* Has a planned concurrent surgical procedure.~* Has other pre existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.~* Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.~* Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.~* Has taken NSAIDs within 10 days prior to the scheduled surgery.~* Has taken opioids within 24 hours prior to the scheduled surgery (3 days for long-acting).~* Has been administered bupivacaine within 5 days prior to the scheduled surgery.~* Has initiated treatment with medications within 1 month prior to study drug administration that can impact pain control.~* Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug.~* Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.~* Has a known history of Hepatitis B, human immunodeficiency virus (HIV), or active Hepatitis C.~* Has uncontrolled anxiety, psychiatric, or neurological disorder that, in the opinion of the Investigator, might interfere with study assessments.~* Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.~* Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. Note: Subjects with a positive drug screen who are taking an allowed, prescribed medication that is known to result in a positive drug test (eg, amphetamine and dextroamphetamine for attention deficit/hyperactivity disorder) may be eligible for participation in the study. Subjects taking medical marijuana are not allowed to participate in the study.~* Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half lives.~* Has undergone 3 or more surgeries within 12 months.~* Has a body mass index (BMI) \>39 kg/m2.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group 1: HTX-011 (Type: EXPERIMENTAL): HTX 011 (bupivacaine/meloxicam)
- Treatment Group 2: Bupivacaine HCI (Type: ACTIVE_COMPARATOR): Bupivacaine HCl
- Treatment Group 3: Saline Placebo (Type: PLACEBO_COMPARATOR): Saline placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete